205 related articles for article (PubMed ID: 22896668)
1. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG.
Hasenstein JR; Shin HC; Kasmerchak K; Buehler D; Kwon GS; Kozak KR
Mol Cancer Ther; 2012 Oct; 11(10):2233-42. PubMed ID: 22896668
[TBL] [Abstract][Full Text] [Related]
2. Triolimus: A Multi-Drug Loaded Polymeric Micelle Containing Paclitaxel, 17-AAG, and Rapamycin as a Novel Radiosensitizer.
Tomoda K; Tam YT; Cho H; Buehler D; Kozak KR; Kwon GS
Macromol Biosci; 2017 Jan; 17(1):. PubMed ID: 27365266
[TBL] [Abstract][Full Text] [Related]
3. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of paclitaxel and tanespimycin in lipid nanoparticles enhanced anti-gastric-tumor effect in vitro and in vivo.
Ma L; Yang D; Li Z; Zhang X; Pu L
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):904-911. PubMed ID: 29757014
[TBL] [Abstract][Full Text] [Related]
5. Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis.
Katragadda U; Fan W; Wang Y; Teng Q; Tan C
PLoS One; 2013; 8(3):e58619. PubMed ID: 23505544
[TBL] [Abstract][Full Text] [Related]
6. The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.
Pledgie-Tracy A; Billam M; Hacker A; Sobolewski MD; Woster PM; Zhang Z; Casero RA; Davidson NE
Cancer Chemother Pharmacol; 2010 May; 65(6):1067-81. PubMed ID: 19727732
[TBL] [Abstract][Full Text] [Related]
7. Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.
Shin DH; Kwon GS
Int J Pharm; 2017 Feb; 518(1-2):307-311. PubMed ID: 28062368
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
Nguyen DM; Lorang D; Chen GA; Stewart JH; Tabibi E; Schrump DS
Ann Thorac Surg; 2001 Aug; 72(2):371-8; discussion 378-9. PubMed ID: 11515869
[TBL] [Abstract][Full Text] [Related]
9. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.
Shin HC; Alani AW; Cho H; Bae Y; Kolesar JM; Kwon GS
Mol Pharm; 2011 Aug; 8(4):1257-65. PubMed ID: 21630670
[TBL] [Abstract][Full Text] [Related]
10. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
11. Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery.
Cho H; Kwon GS
J Drug Target; 2014 Aug; 22(7):669-77. PubMed ID: 24964052
[TBL] [Abstract][Full Text] [Related]
12. 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.
Lee KH; Jang AH; Yoo CG
Am J Respir Cell Mol Biol; 2015 Sep; 53(3):412-21. PubMed ID: 25633180
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T; McSheehy PM; Wartmann M; Lassota P; Brandt R; Lane HA
Anticancer Drugs; 2011 Jan; 22(1):58-78. PubMed ID: 20890178
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.
Shin HC; Cho H; Lai TC; Kozak KR; Kolesar JM; Kwon GS
J Control Release; 2012 Oct; 163(1):93-9. PubMed ID: 22549011
[TBL] [Abstract][Full Text] [Related]
15. Tunicamycin potentiates paclitaxel-induced apoptosis through inhibition of PI3K/AKT and MAPK pathways in breast cancer.
Huang S; Wang D; Zhang S; Huang X; Wang D; Ijaz M; Shi Y
Cancer Chemother Pharmacol; 2017 Oct; 80(4):685-696. PubMed ID: 28779263
[TBL] [Abstract][Full Text] [Related]
16. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
17. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
[TBL] [Abstract][Full Text] [Related]
18. Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects.
Song W; Tang Z; Li M; Lv S; Sun H; Deng M; Liu H; Chen X
Acta Biomater; 2014 Mar; 10(3):1392-402. PubMed ID: 24316362
[TBL] [Abstract][Full Text] [Related]
19. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors.
Yu K; Lucas J; Zhu T; Zask A; Gaydos C; Toral-Barza L; Gu J; Li F; Chaudhary I; Cai P; Lotvin J; Petersen R; Ruppen M; Fawzi M; Ayral-Kaloustian S; Skotnicki J; Mansour T; Frost P; Gibbons J
Cancer Biol Ther; 2005 May; 4(5):538-45. PubMed ID: 15846106
[TBL] [Abstract][Full Text] [Related]
20. Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles.
Han Y; He Z; Schulz A; Bronich TK; Jordan R; Luxenhofer R; Kabanov AV
Mol Pharm; 2012 Aug; 9(8):2302-13. PubMed ID: 22681126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
